Mild primary hyperparathyroidism: Vitamin D deficiency and cardiovascular risk markers

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 7, 2011, Pages 2112-2118

  Farahnak, Parastou ^a,b   Lärfars, Gerd ^a,b   Sten Linder, Margareta ^a,c   Nilsson, Inga Lena ^a,c  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; C REACTIVE PROTEIN; HOMOCYSTEINE; PARATHYROID HORMONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOMATOMEDIN C; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; FEMALE; HUMAN; INFLAMMATION; MALE; METABOLISM; MILD PRIMARY HYPERPARATHYROIDISM; POSTOPERATIVE PERIOD; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; VITAMIN D DEFICIENCY;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CALCIUM; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; INSULIN-LIKE GROWTH FACTOR I; LIPIDS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PARATHYROIDECTOMY; PROSPECTIVE STUDIES; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 79960107705     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0238     Document Type: Article

References (47)

1. Hedbäck G, Odén A 1998 Increased risk of death from primary hyperparathyroidism - an update. Eur J Clin Invest 28:271-276 (Pubitemid 28188301)
2. Lundgren E, Ljunghall S, AkerströmG, Hetta J, Mallmin H, Rastad J 1998 Case-control study on symptoms and signs of "asymptomatic" primary hyperparathyroidism. Surgery 124:980-985; discussion 985-986
3. Palmér M, Adami HO, Bergström R, Akerström G, Ljunghall S 1987 Mortality after surgery for primary hyperparathyroidism: a follow-up of 441 patients operated on from 1956 to 1979. Surgery 102:1-7
4. Nilsson IL, Yin L, Lundgren E, Rastad J, Ekbom A 2002 Clinical presentation of primary hyperparathyroidism in Europe: nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 17(Suppl 2):N68-N74 (Pubitemid 35222315)
5. Farahnak P, Ring M, Caidahl K, Farnebo LO, Eriksson MJ, Nilsson IL 2010 Cardiac function in mild primary hyperparathyroidism and the outcome after parathyroidectomy. Eur J Endocrinol 163:461-467
6. Wermers RA, Khosla S, Atkinson EJ, Grant CS, Hodgson SF, O'Fallon WM, Melton 3rd LJ 1998 Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med 104: 115-122 (Pubitemid 28117404)
7. Hagström E, Lundgren E, Lithell H, Berglund L, Ljunghall S, Hellman P, Rastad J 2002 Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: Population-based study over five years. Clin Endocrinol (Oxf) 56:253-260 (Pubitemid 34233964)
8. Nilsson IL, Aberg J, Rastad J, Lind L 1999 Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy. Surgery 126:1049-1055
9. Erem C, Kocak M, Hacihasanoglu A, Yilmaz M, Saglam F, Ersoz HO2008 Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-dimer levels. Exp Clin Endocrinol Diabetes 116: 619-624
10. Fallo F, Cella G, Casonato A, Ermani M, Vettor R, Zanella S, Lumachi F 2006 Biochemical markers of endothelial activation in primary hyperparathyroidism. Horm Metab Res 38:125-129
11. May M, Lawlor DA, Patel R, Rumley A, Lowe G, Ebrahim S 2007 Associations of von Willebrand factor, fibrin D-dimer and tissue plasminogen activator with incident coronary heart disease: British Women's Heart and Health Cohort Study. Eur J Cardiovasc Prev Rehabil 14:638-645 (Pubitemid 47556400)
12. Whincup PH, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD 2002 Von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 23: 1764-1770 (Pubitemid 35334269)
13. Anderson JL, May HT, Horne BD, Bair TL, Hall NL, Carlquist JF, Lappé DL, Muhlestein JB 2010 Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 106:963-968
14. Holick MF 2007 VitaminD deficiency. N Engl J Med 357:266-281
15. Boudou P, Ibrahim F, Cormier C, Sarfati E, Souberbielle JC 2006 A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest 29:511-515 (Pubitemid 44164892)
16. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L 2005 Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf) 63:506-513 (Pubitemid 41626744)
17. Norman J, Goodman A, Politz D 2010 Calcium, parathyroid hormone, and vitaminD in patients with primary hyperparathyroidism: normograms developed from 10,000 cases. Endocr Pract 6:1-26
18. Bilezikian JP, Khan AA, Potts Jr JT 2009 Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 94:335-339
19. Adams JS, Hewison M 2010 Update in vitamin D. J Clin Endocrinol Metab 95:471-478
20. Zittermann A 2006 Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 92: 39-48 (Pubitemid 43831966)
21. RaoDS, Agarwal G, Talpos GB, Phillips ER, Bandeira F, Mishra SK, Mithal A 2002 Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res 17(Suppl 2): N75-N80 (Pubitemid 35222316)
22. Silverberg SJ 2007 Vitamin D deficiency and primary hyperparathyroidism. J Bone Miner Res 22(Suppl 2):V100-V104 (Pubitemid 351304659)
23. Lumb GA, Stanbury SW 1974 Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism. Am J Med 56:833-839
24. Rao DS, Honasoge M, Divine GW, Phillips ER, Lee MW, Ansari MR, Talpos GB, Parfitt AM 2000 Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab 85:1054-1058 (Pubitemid 32269349)
25. Lalor BC, Mawer EB, Davies M, Lumb GA, Hunt L, Adams PH 1989 Determinants of the serum concentration of 1,25-dihydroxyvitamin D in primary hyperparathyroidism. Clin Sci (Lond) 76:81-86 (Pubitemid 19039095)
26. Mosekilde L, Charles P, Lindegreen P 1989 Determinants for serum 1,25-dihydroxycholecalciferol in primary hyperparathyroidism. Bone Miner 5:279-290 (Pubitemid 19065490)
27. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L 2006 Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study. Eur J Endocrinol 155:237-244 (Pubitemid 44269440)
28. Bilezikian JP, Meng X, Shi Y, Silverberg SJ 2000 Primary hyperparathyroidism in women: a tale of two cities - New York and Beijing. Int J Fertil Womens Med 45:158-165 (Pubitemid 30619114)
29. Lundgren E, Rastad J, Ridefelt P, Juhlin C, Akerström G, Ljunghall S 1992 Long-term effects of parathyroid operation on serum calcium and parathyroid hormone values in sporadic primary hyperparathyroidism. Surgery 112:1123-1129 (Pubitemid 23008241)
30. Untch BR, Barfield ME, Dar M, Dixit D, Leight Jr GS, Olson Jr JA 2007 Impact of 25-hydroxyvitamin D deficiency on perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism. Surgery 142:1022-1026 (Pubitemid 350184115)
31. Grey A, Bolland M, Reid IR 2005 Evaluation and treatment of primary hyperparathyroidism. JAMA 294:2699-2700
32. Silverberg SJ, Shane E, Dempster DW, Bilezikian JP 1999 The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 107:561-567
33. Nordenström E, Westerdahl J, Bergenfelz A 2009 Effect on bone density of postoperative calcium and vitamin-d supplementation in patients with primary hyperparathyroidism: a retrospective study. Langenbecks Arch Surg 394:461-467
34. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 2001 Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497
35. Andersson P, Rydberg E, Willenheimer R 2004 Primary hyperparathyroidism and heart disease: a review. Eur Heart J 25:1776-1787 (Pubitemid 39330228)
36. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, Levy D 2001 Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345:1291-1297
37. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldius G 2003 Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361:777-780 (Pubitemid 36293636)
38. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, Mc- Queen M, Budaj A, Pais P, Varigos J, Lisheng L 2004 Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937-952 (Pubitemid 39208455)
39. Ridker PM, Silvertown JD 2008 Inflammation, C-reactive protein, and atherothrombosis. J Periodontol 79:1544-1551
40. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon 3rd RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith Jr SC, Taubert K, Tracy RP, Vinicor F 2003 Markers of inflammation and cardiovascular disease: application to clinical and public health practice.Astatement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 107:499-511
41. Martinelli I 2005 Von willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol 42:49-55 (Pubitemid 40127270)
42. Bollerslev J, Rosen T, Mollerup CL, Nordenström J, Baranowski M, Franco C, Pernow Y, Isaksen GA, Godang K, Ueland T, Jansson S 2009 Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J Clin Endocrinol Metab 94:2255-2261
43. Hamsten A, Wiman B, de Faire U, Blombäck M 1985 Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.NEngl J Med 313:1557-1563
44. Juhan-Vague I, Alessi MC, Vague P 1991 Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 34:457-462
45. Olofsson BO, Dahlén G, Nilsson TK 1989 Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 10:77-82 (Pubitemid 19048323)
46. Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O 2009 Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism. Eur J Endocrinol 160:863-868
47. Homocysteine Studies Collaboration 2002 Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288: 2015-2022